Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, highlighted significant advancements in acute myeloid leukemia (AML) treatment, focusing on targeted therapies and combination regimens. He emphasized the role of FLT3 inhibitors, such as quizartinib and gilteritinib, in improving survival rates, particularly when combined with chemotherapy or venetoclax. Dr Daver also discussed the promising use of menin inhibitors like revumenib in treating KMT2A and NPM1-mutated AML, noting high response rates in relapsed/refractory cases. For IDH-mutated AML, triplet therapies combining azacitidine, venetoclax, and IDH inhibitors have shown impressive survival outcomes. Despite progress, he acknowledged the ongoing challenges in treating TP53-mutated AML and the need for innovative approaches, including immunotherapy and bispecific antibodies